The MDM2 inhibitor KRT-232 is currently being evaluated in PV and MF patients (NCT03669965 and NCT03662126), with preliminary results showing clinical activity in higher-risk MF patients who experienced relapse or refractory disease during treatment with a JAK inhibitor [159]. Here, MDM2 is linked to acquired polycythemia vera.